Table 1.
Summary of baseline characteristics in included studies. Q4W: every 4 weeks; Q8W: every 8 weeks
| N° PATIENTS RANDOMIZED | AGE RANGE | BLOOD EOS COUNT | EXACERBATION/YEAR | FEV1% PRED | |
|---|---|---|---|---|---|
| Mepolizumab | |||||
| Ortega et al. (2014) | 576 | 12–81 | 290 ± 1050 | 3.8 ± 2.7 | 59.3 ± 7.5 |
| Bel et al. (2014) | 135 | 16–74 | 250 ± 1245 cell/μl | 3.3 ± 3.4 | 59.6 ± 17.0 |
| Chupp GL et al. (2017) | 556 | ≥12 | 234 (≥150 cell/μl); 186 (≥300 cell/μl) | 2.9 ± 1,9 | 55.5 ± 14.4 |
| Benralizumab | |||||
| Bleecker et al. (2016) | 1205 | 12–75 | 390 Q4W 360 Q8W | 2.9 ± 1.8 Q4W 2.8 ± 1.5 Q8W | 57.4% ± 14.1 Q4W; 56.1% ± 14.6 Q8W |
| Fitzgerald et al. (2016) | 1306 | 12–75 | 370 Q4W 400 Q8W | 2.7 (1.9) Q4W 2.7 (1.4) Q8W | 58.9% ± 14.8 Q4W; 57.9% ± 14.9 Q8W |
| Nair et al. (2017) | 220 | 18–75 | 462 Q4W 437 Q8W | 2.8 ± 2.0 Q4W 3.1 ± 2.8 Q8W | 57.4 ± 18.0 Q4W 59.0 ± 17.9 Q8W |
| Ferguson et al. (2017) | 351 | 18–75 | 205 | 0.3 ± 0.8 | 69.7% ± 10.9 |
| Reslizumab | |||||
| Castro et al. (2015) | 489 | 12–75 | 696 | 1.9 ± 1.6 | 63.6 ± 18.6 |
| Bjermer et al. (2016) | 315 | 12–75 | 648 | 57 (%) | 70.4 |
| Corren et al. (2016) | 496 | 18–65 | 281 | 66 (%) | 66.8 |